Annual Report of the company for FY 2025-26

Date: 19.08.2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Sub: Submission of 25th Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR) Regulations, 2015. In Compliance with Regulation 34 of SEBI (LODR) Regulations, 2015, we are herewith submitting the 25th Annual Report for the Financial Year 2025-26 of the Company, which is dispatched to our shareholders on 19th August, 2026. The Annual General Meeting of the Company is scheduled to be held on Thursday, 10th September, 2026 at 11:00 A.M. through Video Conference “VC” / Other Audio-Visual Means. Further, pursuant to Regulation 36(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a letter providing the web-link of the Annual Report, being sent to those members who have not registered their e-mail address, is available on the Company’s website at https://www.saiparenterals.com/. This is for the information and records of the exchange, please. Thanking You, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) A Stronger Foundation; A Wider Reach ANNUAL REPORT 2025-26 Contents 02-34 35-118 Corporate Overview Statutory Reports About us 02 Notice 35 Our journey 04 Board’s Report 76 Chairman and MD’s message 06 Corporate Governance Report 87 Financial performance 08 Management Discussion Global presence 09 & Analysis Report Our products 10 121-247 Our manufacturing network 13 Our business model 16 Financial Statements Research and Development (R&D) 18 People at the Core 22 Standalone Financial Statements 121 Environment 24 Consolidated Financial Statements 186 Corporate Social Responsibility (CSR) 26 Governance 28 Board of Directors 30 Promoters and Business Leadership 32 Senior Management Team 32 Growth outlook 33 For more information, please scan the QR code Corporate information 34 or visit our website: www.saiparenterals.com A Stronger For Sai Parenterals, our journey has been Our branded generics business provides an established base, while our rapidly scaling CDMO platform is opening new avenues across international markets. Our growing focus on injectables, supported by shaped by perseverance, resilience and an specialised manufacturing capabilities, is enabling us to address more complex and critical therapies. Foundation; unwavering commitment to execution. Over At the same time, investments in R&D are expanding our product pipeline and enhancing our ability to the years, we have built capabilities across develop formulations aligned with evolving market needs. pharmaceutical manufacturing, product These capabilities are supported by a manufacturing network built for scale and diversity. With five A Wider development and regulatory affairs that facilities and approximately 1,160 million units of installed annual capacity, we have the capacity to serve a broader portfolio across dosage forms and geographies. This foundation is also enabling us are now creating opportunities beyond our to extend our presence internationally. Through Noumed, we have established a direct presence in Reach established markets and offerings. What Australia and New Zealand, gaining access to established customer relationships, regulatory dossiers began with a strong foundation in branded and OTC opportunities. The renewal of our ₹1,300 Crore OTC medicines supply agreement in Australia further reflects the depth of these relationships and the confidence they place in our capabilities. generics is evolving into a more integrated pharmaceutical platform, with greater Our transition into a listed Company marks another important chapter in this journey, bringing greater visibility, broader opportunities and a heightened sense of responsibility. As we look ahead, our participation in regulated markets and investments are focused on translating the capabilities we have built into new opportunities: expanding higher-value segments. access to regulated markets, advancing our injectables portfolio, deepening our R&D pipeline, scaling CDMO opportunities and integrating our international operations. We are growing from strength to strength, broadening our geographical footprint, exploring new possibilities and establishing a larger role in the global pharmaceutical landscape. SAI Parenteral’s Limited Corporate Overview Statutory Reports Financial Statements About us Safeguarding healthcare, A defining milestone Our successful listing on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) marked a pivotal transforming lives achievement in our evolution. With our emergence as a listed Company, we are well positioned to pursue our growth trajectory while retaining long-term value for all our stakeholders. We, at Sai Parenterals Limited, are a diversified multinational pharmaceutical Company with over two decades of proven manufacturing expertise and global reach. Since our inception in parenteral medicines, we have evolved into a formulations organisation with a comprehensive range of capabilities spanning injectables, oral solids, oral liquids and topical preparations. We optimise our operations through two business verticals, Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) Services, catering to our diverse portfolio of therapy areas. Our customer base includes central and state government agencies, pharmaceutical organisations Indian institutions and channel partners, with our products progressively reaching regulated and semi regulated markets at a global scale. 50+ Our integrated capabilities across product development, manufacturing and regulatory affairs equip us with the Global Markets capacity to widely deliver end to end pharmaceutical solutions, from formulation development and scale up to commercial production. Backed by robust Research 302 and Development (R&D), advanced manufacturing infrastructure and Current Good Manufacturing Practice (cGMP) compliant facilities, we specialise in generic Products and complex generic formulations across a multitude of therapy areas. Purpose Commitment to making essential medicines accessible and affordable Our strengths Integrity founding Uncompromising quality standards principles and ethical business practices Product Development Regulatory Strength Global Reach Proficiency in complex generics, Reliable capabilities in dossier Established geographical differentiated formulations and development, global filings and footprints pan-India and Self-Reliance advanced dosage forms regulatory compliance internationally Building independent manufacturing capabilities for healthcare needs 02 Annual Report 2025-26 03 SAI Parenteral’s Limited Corporate Overview Statutory Reports Financial Statements Our journey A track record of our growth trajectory 1988 2016 2025 2022 Foundation Ownership Change Global Expansion Growth at Scale Incorporation of Revat Alteration in the ownership of the Set up of Sai Parenterals Pte. Limited in Singapore Laboratories Private Limited by Company by acquisition of 100% Equity Achieved a turnover of ₹100 Crore current promoters Shares by existing Promoters Acquired Australian-based Noumed Pharmaceuticals Pty Limited Acquired New Zealand-based Noumed Pharmaceuticals Ltd 2001 2021 2023 Filed 45 product registrations with FDA, Philippines Incorporation Expansion and Growth Strategic Acquisitions Incorporation of Sai Parenteral’s Private Limited Incorporation of Revat Laboratories Acquired Revat Laboratories Pvt 2026 Pvt Ltd by current promoters Ltd as a wholly owned subsidiary Acquired PICS-approved Public Listing Cephalosporin plant (Unit IV) Completed IPO in March 2026 with Acquired TGA-approved Australia a primary fund raise of ₹285 Crore plant (Unit II [Showing first 8,000 characters — download PDF for full document]